Biotech News & Trading Forum: Community User: Weedmaster

ACST – Acasti Pharma Inc. CaPre (TRILOGY 1 and 2) Hypertriglyceridemia Phase 3 top-*** data due in January 2020 from both trials. MK: $191.7 million  AXSM – Axsome Therapeutics Inc. AXS-05 STRIDE-1 Treatment resistant depression Phase 3 data due 1Q 2020. MK: $3.3 billion BHVN – Biohaven Pharmaceutical Holding Company Ltd. Rimegepant Migraine - preventative Phase 3 top-*** data due early-1Q 2020. MK: $3 billion EXEL – Exelixis Inc., BMY – Bristol-Myers Squibb Company CABOMETYX (cabozantinib) with Opdivo and Yervoy - CheckMate 9ER First-*** renal cell carcinoma Phase 3 data due early 2020. MK: $5.6 billion GNFT – GENFIT S.A. Elafibranor - RESOLVE-IT Non-alcoholic steatohepatitis (NASH) Phase 3 interim data due 1Q 2020. MK: $805.4 million ITRM – Iterum Therapeutics plc Sulopenem Complicated urinary tract infections (cUTI) Phase 3 data due 1Q 2020. MK: $59.8 million KALA – Kala Pharmaceuticals Inc. KPI‑121 0.25% STRIDE 3 Dry eye disease Phase 3 data due 1Q 2020. MK: $183.9 million KPTI – Karyopharm Therapeutics Inc Selinexor - BOSTON Multiple myeloma Phase 3 data due early 2020. MK: $1.2 billion MIST – Milestone Pharmaceuticals Inc. Etripamil - NODE-301 Paroxysmal supraventricular tachycardia (PSVT) Phase 3 top-*** data due around end of 1Q 2020. MK: $404.1 million MNLO – Menlo Therapeutics Inc. Serlopitant Pruritus associated with prurigo nodularis Phase 3 data due March/April 2020. MK: $136.9 million SNGX – Soligenix Inc. SGX301 (synthetic hypericin) Cutaneous T-Cell Lymphoma (CTCL) cancer Phase 3 completion of enrolment announced December 3, 2019 with top-*** data 1Q 2020. MK: $34.7 million TGTX – TG Therapeutics Inc. TG-1101 and TGR-1202 - UNITY-CLL study Chronic Lymphocytic Leukemia (CLL) and non-Hodgkin's Lymphoma (NHL) Phase 3 PFS data due early 2020. MK: $1.3 billion

22nd Century Group - XXII VLN cigarettes MRTP application FDA Tobacco Products Scientific Advisory Committee (TPSAC) to meet February 14, 2020, regarding MRTP application. https://ir.xxiicentury.com/news-media/press-releases/detail/380/22nd-century-group-to-present-its-modified-risk-tobacco Cash: 43.7mio$ burn: 1mio$/month reicht noch 40 Monate. (30.09.2019) MARKET CAP 135,763,794 SHARES 134,419,598 AV. DAILY VOLUME 2,292,814 http://stocktwits.com/cameron4333/message/189954043 http://stocktwits.com/fnu2/message/189914573 https://ir.xxiicentury.com/news-media/press-releases/detail/375/22nd-century-group-files-2019-third-quarter-report https://ir.xxiicentury.com/news-media/press-releases/detail/376/22nd-century-group-comments-on-delay-of-reduced-nicotine

Grossartiges Forum hier. Danke an @lle für sämtliche Infos, Tipps und den Umgang miteinander.

Danke Gottsbrain für den Hinweis. Dachte wäre etwas Neues. 😅

Für was dann die benachrichtigung? Kann doch jeder errechnen was die 500k anteile nun wert sind 🙄

January 10, 2020 - Fny Investment Advisers, Llc has filed a 13F-HR form disclosing ownership of 500,000 shares of InflaRx N.V. (NASDAQ:IFRX) with total holdings valued at $1,980,000 USD as of December 31, 2019. Fny Investment Advisers, Llc had filed a previous 13F-HR on October 25, 2019 disclosing 500,000 shares of InflaRx N.V. at a value of $1,235,000 USD. This represents a change in shares of 0.00 percent and a change in value of 60.32 percent during the quarter. Die Anteile sind die selben wie im Oktober nur der Wert hat sich geändert weil der Kurs gestiegen ist. Keine geänderten Anteile.

Will ich euch nicht vorenthalten. Gestern Inflarx 13er Insiderkauf. https://fintel.io/so/us/ifrx/fny-investment-advisers

Argh, ich bin statt in Titan in Ritter rein und hab den ersten Schwung nicht genutzt. Mal sehen was da noch geht...Rock on

Lipocine krabbelt auch langsam wieder Gen Norden.

Kempharm 🚀

Hier geht es also ans Eingemachte

Tolle *** :)

Inflarx 🚀

Akari 👍

Die sind mindestens 20$ Wert 😁

Wird wahrscheinlich auch noch zu niedrig sein